Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 3.52% and Operating profit at -26.66% over the last 5 years
2
With a growth in Net Sales of 5.84%, the company declared Very Positive results in Mar 25
3
With ROE of 4.15%, it has a fair valuation with a 1.44 Price to Book Value
4
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,222 Million (Mid Cap)
35.00
NA
0.33%
0.50
4.15%
1.44
Revenue and Profits:
Net Sales:
798 Million
(Quarterly Results - Jun 2025)
Net Profit:
63 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.03%
0%
-7.03%
6 Months
-7.89%
0%
-7.89%
1 Year
41.48%
0%
41.48%
2 Years
6.97%
0%
6.97%
3 Years
5.66%
0%
5.66%
4 Years
-40.22%
0%
-40.22%
5 Years
-55.0%
0%
-55.0%
Zhejiang Tianyu Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.52%
EBIT Growth (5y)
-26.66%
EBIT to Interest (avg)
25.90
Debt to EBITDA (avg)
3.71
Net Debt to Equity (avg)
0.48
Sales to Capital Employed (avg)
0.45
Tax Ratio
11.00%
Dividend Payout Ratio
30.77%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.24%
ROE (avg)
4.61%
Valuation key factors
Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
1.44
EV to EBIT
40.74
EV to EBITDA
13.49
EV to Capital Employed
1.29
EV to Sales
2.42
PEG Ratio
0.06
Dividend Yield
0.33%
ROCE (Latest)
3.17%
ROE (Latest)
4.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
798.20
754.20
5.83%
Operating Profit (PBDIT) excl Other Income
153.80
181.30
-15.17%
Interest
11.30
11.30
Exceptional Items
0.10
0.30
-66.67%
Consolidate Net Profit
63.30
86.20
-26.57%
Operating Profit Margin (Excl OI)
81.70%
122.90%
-4.12%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 5.83% vs 9.10% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -26.57% vs 395.21% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,605.70
2,494.10
4.47%
Operating Profit (PBDIT) excl Other Income
444.20
452.80
-1.90%
Interest
56.00
51.20
9.37%
Exceptional Items
12.00
-5.00
340.00%
Consolidate Net Profit
55.90
27.40
104.01%
Operating Profit Margin (Excl OI)
41.50%
58.50%
-1.70%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 4.47% vs -5.84% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 104.01% vs 123.04% in Dec 2023
About Zhejiang Tianyu Pharmaceutical Co., Ltd. 
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






